There is no definitive, unified view on chemotherapy for T1 pN0M0 breast cancer. Our study explored the effects of chemotherapy on T1 pN0M0 breast cancer.
75,139 patients diagnosed with T1 pN0M0 breast cancer were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate Cox analyses were performed to investigate the effects of chemotherapy on T1a, T1b, and T1c pN0M0 breast cancer, various tumor grades, and four molecular subtypes. Propensity score matching (PSM) was used to eliminate confounding factors and further verify the results between chemotherapy and no chemotherapy. Finally, 545 T1pN0M0 breast cancer patients treated at the Northern Jiangsu People’s Hospital were included for external validation. Univariate and multivariate Cox analyses were used to confirm the role of chemotherapy in T1a, T1b, and T1c pN0M0 breast cancer. Survival curves were plotted using the Kaplan–Meier method for tumor grades and molecular subtypes.
Chemotherapy demonstrated a statistically significant improvement in T1b and T1c breast cancer, not in T1a breast cancer. With T1b breast cancer, chemotherapy had effects on grade III and molecular subtypes hormone receptor+ [HR+]/human epidermal growth factor receptor 2+ [HER2+], HR-/HER2+, and HR-/HER2-. Chemotherapy was beneficial to overall survival for grade II/III and T1c breast cancer. After PSM, identical results were obtained. We also obtained similar results with external validation, except that chemotherapy made a difference in grade II and T1b breast cancer of external validation.
Partial T1 pN0M0 breast cancer patients with tumor grade III T1b pN0M0 except HR+/HER2-, those with tumor grade II and III T1c pN0M0 can obtain overall survival benefits from chemotherapy.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Posted 19 Mar, 2021
On 05 Mar, 2021
On 05 Mar, 2021
On 05 Mar, 2021
On 05 Mar, 2021
Posted 19 Mar, 2021
On 05 Mar, 2021
On 05 Mar, 2021
On 05 Mar, 2021
On 05 Mar, 2021
There is no definitive, unified view on chemotherapy for T1 pN0M0 breast cancer. Our study explored the effects of chemotherapy on T1 pN0M0 breast cancer.
75,139 patients diagnosed with T1 pN0M0 breast cancer were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate Cox analyses were performed to investigate the effects of chemotherapy on T1a, T1b, and T1c pN0M0 breast cancer, various tumor grades, and four molecular subtypes. Propensity score matching (PSM) was used to eliminate confounding factors and further verify the results between chemotherapy and no chemotherapy. Finally, 545 T1pN0M0 breast cancer patients treated at the Northern Jiangsu People’s Hospital were included for external validation. Univariate and multivariate Cox analyses were used to confirm the role of chemotherapy in T1a, T1b, and T1c pN0M0 breast cancer. Survival curves were plotted using the Kaplan–Meier method for tumor grades and molecular subtypes.
Chemotherapy demonstrated a statistically significant improvement in T1b and T1c breast cancer, not in T1a breast cancer. With T1b breast cancer, chemotherapy had effects on grade III and molecular subtypes hormone receptor+ [HR+]/human epidermal growth factor receptor 2+ [HER2+], HR-/HER2+, and HR-/HER2-. Chemotherapy was beneficial to overall survival for grade II/III and T1c breast cancer. After PSM, identical results were obtained. We also obtained similar results with external validation, except that chemotherapy made a difference in grade II and T1b breast cancer of external validation.
Partial T1 pN0M0 breast cancer patients with tumor grade III T1b pN0M0 except HR+/HER2-, those with tumor grade II and III T1c pN0M0 can obtain overall survival benefits from chemotherapy.
Figure 1
Loading...